CCL2 and neoplasm: CXCL2 has also been demonstrated to recruit MDSCs and promote tumor growth in breast cancer, pancreatic ductal adenocarcinoma, oral cancer, and glioblastoma, whereas knockdown of CXCR2 in MDSCs and knockdown of CCL2 reduced the recruitment of MDSCs to tumor sites in mice [34–37].